SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Dynavax DVAX
An SI Board Since August 2004
Posts SubjectMarks Bans Symbol
184 23 0 DVAX
Emcee:  keokalani'nui Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
84Can't remember having seen this, in recent times of "overnight pricing&scaram(o)uche-5/10/2012
83Dynavax Announces Proposed Public Offering of Common Stock BERKELEY, CA, May 0Savant-5/9/2012
82Dynavax Prices 17.5M-Shr Offering At $4.25/Shr >DVAXSavant-5/9/2012
81Dynavax Embarks on Transition to Commercialization BERKELEY, CA, May 08, 2012 Savant-5/8/2012
80Dynavax Reports First Quarter 2012 Financial Results BERKELEY, CA, Apr 27, 201Savant-4/27/2012
79Dynavax Reports Final Phase 3 Data for HEPLISAV(TM) in CKD Patients and New DataSavant-3/27/2012
78Phase 3 Data on HEPLISAV(TM) in Adults Aged 40-70 Published in VACCINE BERKELESavant-3/13/2012
77Dynavax Reports Fourth Quarter and Year End 2011 Financial Results BERKELEY, CSavant-3/6/2012
76Dynavax to Present at Two Upcoming Investor Healthcare Conferences BERKELEY, CSavant-2/14/2012
75Phase 3 Data on HEPLISAV(TM) in Adults Aged 18-55 Published in VACCINE BERKELESavant-2/13/2012
74Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist foSavant-12/21/2011
73Dynavax Initiates Proof of Mechanism Trial in Lupus Patients Milestone PaymentSavant-12/20/2011
72Dynavax Prices Public Offering of Common Stock BERKELEY, CA, Nov 03, 2011 (MARSavant-11/4/2011
71Dynavax Confirms HEPLISAV(TM) Submission Strategies With U.S. FDA and EMA BERKSavant-10/28/2011
70Dynavax Reports Positive Immunogenicity Data From an Analysis of Hypo-ResponsiveSavant-10/10/2011
69Dynavax to Report Additional Immunogenicity Data for HEPLISAV(TM) Phase 3 Trial Savant-9/16/2011
68Dynavax Receives $600,000 SBIR Grant for TLR Research BERKELEY, CA, Sep 07, 20Savant-9/7/2011
67Dynavax to Present at William Blair & Company's 2011 Life Sciences ConfeSavant-9/1/2011
66Dynavax to Present at the Wedbush 2011 Life Sciences Conference BERKELEY, CA, Savant-8/11/2011
65FDA Agrees With Dynavax on Consistency of HEPLISAV(TM) Lots BERKELEY, CA, Jul Savant-7/28/2011
64[Text Chart]Savant-7/25/2011
63Dynavax Techs $61.7M Cash, Equivalents, Mktable Securities At June 30Savant-7/20/2011
62Dynavax Phase 3 Demonstrates Superiority and Safety of HEPLISAV(TM) vs. Engerix-Savant-7/20/2011
61Dynavax Initiates First Human Trial in Lupus Program Apr 20, 2011 12:30:15 (ETSavant-4/25/2011
60Dynavax Reports Fourth Quarter and Year End 2010 Financial Results BERKELEY, CASavant-3/8/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News